Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

NCT03910712 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Female
HER2-positive Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
Metastatic Breast Cancer
Breast Diseases
Hormone Receptor Positive Tumor

Interventions

DRUG: Pyrotinib
DRUG: Trastuzumab
DRUG: Aromatase inhibitor

Sponsor

Peking Union Medical College Hospital